InspireMD Retained Earnings (Accumulated Deficit) 2013-2024 | NSPR
InspireMD retained earnings (accumulated deficit) from 2013 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
| InspireMD Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $-254 |
| 2023 | $-222 |
| 2022 | $-202 |
| 2021 | $-183 |
| 2020 | $-168 |
| 2019 | $-158 |
| 2018 | $-148 |
| 2017 | $-140 |
| 2016 | $-132 |
| 2015 | $-123 |
| 2014 | $-107 |
| 2013 | $-82 |
| 2013 | $-73 |
| 2012 | $0 |
| 2012 | $-44 |
| 2011 | $-44 |
| InspireMD Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-254 |
| 2024-09-30 | $-244 |
| 2024-06-30 | $-236 |
| 2024-03-31 | $-229 |
| 2023-12-31 | $-222 |
| 2023-09-30 | $-216 |
| 2023-06-30 | $-211 |
| 2023-03-31 | $-206 |
| 2022-12-31 | $-202 |
| 2022-09-30 | $-197 |
| 2022-06-30 | $-192 |
| 2022-03-31 | $-188 |
| 2021-12-31 | $-183 |
| 2021-09-30 | $-179 |
| 2021-06-30 | $-175 |
| 2021-03-31 | $-171 |
| 2020-12-31 | $-168 |
| 2020-09-30 | $-164 |
| 2020-06-30 | $-162 |
| 2020-03-31 | $-160 |
| 2019-12-31 | $-158 |
| 2019-09-30 | $-155 |
| 2019-06-30 | $-153 |
| 2019-03-31 | $-151 |
| 2018-12-31 | $-148 |
| 2018-09-30 | $-145 |
| 2018-06-30 | $-143 |
| 2018-03-31 | $-143 |
| 2017-12-31 | $-140 |
| 2017-09-30 | $-139 |
| 2017-06-30 | $-137 |
| 2017-03-31 | $-134 |
| 2016-12-31 | $-132 |
| 2016-09-30 | $-130 |
| 2016-06-30 | $-128 |
| 2016-03-31 | $-126 |
| 2015-12-31 | $-123 |
| 2015-09-30 | $-120 |
| 2015-06-30 | $-117 |
| 2015-03-31 | $-113 |
| 2014-12-31 | $-107 |
| 2014-09-30 | $-103 |
| 2014-06-30 | $-96 |
| 2014-03-31 | $-88 |
| 2013-12-31 | $-82 |
| 2013-09-30 | $-77 |
| 2013-06-30 | $-73 |
| 2013-03-31 | $-58 |
| 2012-12-31 | $-53 |
| 2012-09-30 | $-51 |
| 2012-06-30 | $-44 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.080B | $0.007B |
| InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel. | |||